ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase December 19, 2022
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement December 13, 2022
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections November 28, 2022
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections September 12, 2022
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection September 12, 2022
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 15, 2022
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis August 15, 2022
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis July 13, 2022
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections June 14, 2022
